Endpoints News
The Iran war is hitting pharma supply chains Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
12 May, 2026
US Pharma and Biotech Summit - May 14, 2026
Policy shifts, regulatory unknowns, and a dealmaking environment that won’t sit still — US biopharma is navigating serious uncertainty. Join FT Live and Endpoints News for the conversations that will define what comes next.
presented by Premier, Inc.
Ex­ec­u­tive Brief: How to Fu­ture-Proof and Dif­fer­en­ti­ate Your Busi­ness with RWD/RWE
top stories
1. Updated: FDA Commissioner Makary to resign, source says
2. Iran war disruptions begin to emerge upstream of the pharma supply chain
3. EU reaches provisional deal on Critical Medicines Act
4. Optum Rx unveils pharmacy model with clear fees, building on transparency push
5. Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
6. Pfizer and Arvinas give disappointing breast cancer drug to Rigel
7. Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
8. Five burning questions for Isomorphic after its mammoth $2B+ raise
more stories
 
Lydia Ramsey Pflanzer
.

Well, it's official: FDA Commissioner Marty Makary is set to resign, Max Bayer reports. The move ends months of uncertainty about Makary's future at the agency.

.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
Marty Makary (Jose Luis Magana/AP Images)
1
by Max Bayer

FDA Com­mis­sion­er Mar­ty Makary is set to re­sign af­ter his job sta­tus hung in the bal­ance for days.

A source fa­mil­iar with the com­mis­sion­er's think­ing...

Read full story
An oil tanker sits at anchor in the Strait of Hormuz off Bandar Abbas, Iran, on May 2, 2026. (Amirhosein Khorgooi/ISNA via AP)
2
by Anna Brown

As the Iran war en­ters its third month, its knock-on ef­fects on raw ma­te­ri­als, en­er­gy costs and ship­ping are be­gin­ning to be felt in the...

Read full story
3
by Anna Brown

The Crit­i­cal Med­i­cines Act reached its next mile­stone on Tues­day, af­ter the Eu­ro­pean Par­lia­ment and the Coun­cil pro­vi­sion­al­ly vot­ed it through.

The pro­posed reg­u­la­tion aims...

Read full story
4
by Shelby Livingston

Unit­ed­Health Group’s Op­tum Rx on Mon­day un­veiled a new ap­proach to pre­scrip­tion drug ben­e­fits that it said of­fers its cus­tomers trans­paren­cy in­to the en­tire drug...

Read full story
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
5
by Ayisha Sharma

Bay­er is back on the mar­ket for drug ac­qui­si­tions af­ter a half-decade on the side­lines, ac­cord­ing to CEO Bill An­der­son.

“We’re go­ing to be care­ful...

Read full story
<